Izzo NJ[au] - Search Results

Year	Number of Results
1987	1
1988	3
1989	1
1990	2
1994	3
1995	1
1998	1
2001	1
2003	1
2005	2
2006	1
2007	1
2008	2
2009	1
2014	2
2019	1
2020	3
2021	5
2022	1

1

The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease.

Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, Fillit H, Harrison JE, Schneider LS, Scheltens P, de Haan W, Grundman M, van Dyck CH, Izzo NJ, Catalano SM; Synaptic Health Endpoints Working Group. Colom-Cadena M, et al. Among authors: izzo nj. Alzheimers Res Ther. 2020 Mar 2;12(1):21. doi: 10.1186/s13195-020-00588-4. Alzheimers Res Ther. 2020. PMID: 32122400 Free PMC article. Review.

2

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.

Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, Waybright L, Look G, Rishton G, Safferstein H, Hamby ME, Williams C, Sadlek K, Edwards HM, Davis CS, Grundman M, Schneider LS, DeKosky ST, Chelsky D, Pike I, Henstridge C, Blennow K, Zetterberg H, LeVine H 3rd, Spires-Jones TL, Cirrito JR, Catalano SM. Izzo NJ, et al. Alzheimers Dement. 2021 Aug;17(8):1365-1382. doi: 10.1002/alz.12302. Epub 2021 Feb 8. Alzheimers Dement. 2021. PMID: 33559354 Free PMC article. Clinical Trial.

3

HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte.

Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, Izzo NJ Jr. Claycomb WC, et al. Among authors: izzo nj jr. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2979-84. doi: 10.1073/pnas.95.6.2979. Proc Natl Acad Sci U S A. 1998. PMID: 9501201 Free PMC article.

4

Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson's patient brain-derived α-synuclein.

Limegrover CS, Yurko R, Izzo NJ, LaBarbera KM, Rehak C, Look G, Rishton G, Safferstein H, Catalano SM. Limegrover CS, et al. Among authors: izzo nj. J Neurosci Res. 2021 Apr;99(4):1161-1176. doi: 10.1002/jnr.24782. Epub 2021 Jan 22. J Neurosci Res. 2021. PMID: 33480104 Free PMC article.

5

Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's Disease.

Rishton GM, Look GC, Ni ZJ, Zhang J, Wang Y, Huang Y, Wu X, Izzo NJ, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, Catalano SM. Rishton GM, et al. Among authors: izzo nj. ACS Med Chem Lett. 2021 Aug 9;12(9):1389-1395. doi: 10.1021/acsmedchemlett.1c00048. eCollection 2021 Sep 9. ACS Med Chem Lett. 2021. PMID: 34531947

6

Modeling the mature CNS: A predictive screening platform for neurodegenerative disease drug discovery.

LaBarbera KM, Limegrover C, Rehak C, Yurko R, Izzo NJ, Knezovich N, Watto E, Waybright L, Catalano SM. LaBarbera KM, et al. Among authors: izzo nj. J Neurosci Methods. 2021 Jul 1;358:109180. doi: 10.1016/j.jneumeth.2021.109180. Epub 2021 Apr 6. J Neurosci Methods. 2021. PMID: 33836174 Free PMC article.

7

Proceedings from the Fourth International Symposium on σ-2 Receptors: Role in Health and Disease.

Izzo NJ, Colom-Cadena M, Riad AA, Xu J, Singh M, Abate C, Cahill MA, Spires-Jones TL, Bowen WD, Mach RH, Catalano SM. Izzo NJ, et al. eNeuro. 2020 Nov 4;7(6):ENEURO.0317-20.2020. doi: 10.1523/ENEURO.0317-20.2020. Print 2020 Nov/Dec. eNeuro. 2020. PMID: 33028631 Free PMC article. Review.

8

Alzheimer's protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity.

Limegrover CS, LeVine H 3rd, Izzo NJ, Yurko R, Mozzoni K, Rehak C, Sadlek K, Safferstein H, Catalano SM. Limegrover CS, et al. Among authors: izzo nj. J Neurochem. 2021 May;157(4):1316-1330. doi: 10.1111/jnc.15212. Epub 2020 Oct 25. J Neurochem. 2021. PMID: 33025581 Free PMC article.

9

Sustained hypoxia enhances chondrocyte matrix synthesis.

Coyle CH, Izzo NJ, Chu CR. Coyle CH, et al. Among authors: izzo nj. J Orthop Res. 2009 Jun;27(6):793-9. doi: 10.1002/jor.20816. J Orthop Res. 2009. PMID: 19051248 Free PMC article.

10

A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.

Grundman M, Morgan R, Lickliter JD, Schneider LS, DeKosky S, Izzo NJ, Guttendorf R, Higgin M, Pribyl J, Mozzoni K, Safferstein H, Catalano SM. Grundman M, et al. Among authors: izzo nj. Alzheimers Dement (N Y). 2019 Jan 23;5:20-26. doi: 10.1016/j.trci.2018.11.001. eCollection 2019. Alzheimers Dement (N Y). 2019. PMID: 30723776 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results